Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - November 20, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/16 - Castle Creek Pharmaceuticals Announces License of Exclusive U.S. Rights for Arlevert from Hennig Arzneimittel GmbH
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
12/31/16 - Ebola vaccine shows promise An experimental vaccine against Ebola is 100 percent effective in clinical trials
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
12/31/16 - Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial [Saudi Press Agency (Saudi Arabia)]
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
12/31/16 - Pharmacist: New medications help with dry eyes, seizures and hallucinations
In 2016, many new and useful medications got FDA approval. My articles are syndicated worldwide, but I'm only listing English drug names so please ask your local pharmacist to translate the medication name for your country. So the FDA approved this injectable drug to help people who have been exposed from infected animals, contaimated animal produc
12/31/16 - TapImmune: Year End 2016 Update
TapImmune, Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today issued its year-end 2016 update. Below is the statement from Glynn Wilson, Ph.D., Chairman and CEO of TapImmune:. As you are well a
12/31/15 - AHF: Ohio Certifies Voter Signatures In Support of Drug Pricing Initiative, Clears Hurdle for November Ballot
The Ohio Secretary of State certified yesterday 116,015 signatures of registered Ohio voters who support the Ohio Drug Price Relief Act, a proposed statewide ballot initiative that will revise Ohio law to require state programs pay the same or less for prescription medications as the U.S. Department of Veterans Affairs. Drug pricing advocates affil
12/31/15 - Alexion Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Dec. 31 Alexion Pharmaceuticals, Cheshire, Connecticut, has been assigned a patent developed by four co-inventors for "methods of treating complement-associated disorders with anti-C5a antibodies." The co-inventors are Russell P. Rother, Oklahoma City, Douglas L. Sheridan, Branford, Connecticut, Paul P. Tamburini, Kensington, Con
12/31/15 - Basilea provides clinical program updates
Release date- 28122015- Basilea Pharmaceutica Ltd. today provided an update on the planned clinical phase 3 development program for its antibiotic ceftobiprole in the United States and reported completion of patient recruitment and interim data from the ongoing phase 1/ 2 a study with the intravenous formulation of its oncology drug candidate BAL10
12/31/15 - Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence [Tripoli Post, The (Libya)]
-Princeton, New Jersey and Lund, Sweden 30 December 2015 Braeburn. Pharmaceuticals and Camurus announce that the first patient has been randomized. in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent.
12/31/15 - Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib
By a News Reporter-Staff News Editor at Politics& Government Week Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for Clovis' New Drug Application for rociletinib by the standard extension period of three months with the new goal date of June 28, 2016. Clovis Oncology
12/31/15 - Collegium Pharmaceutical Provides Update on Orange Book-Listed Patent Suits [Global Data Point]
The three patents have been previously invalidated for obviousness by the court in the Southern District of New York in Purdue Pharma, L.P.' s suit against Teva Pharmaceuticals USA, Inc. Purdue appealed the obviousness ruling to the Federal Circuit, which heard oral arguments on November 3, 2015.&# x0D;. Purdue's initiation of a patent infringement
12/31/15 - Court: Killer's conversations with husband not confidential
Sheila Davalloo, 46, formerly of Pleasantville, New York, tried to prevent her husband from testifying at her trial in 2012, citing the marital communications privilege in state law. Raymundo was beaten and stabbed nearly 20 times in her Stamford condominium. The three worked together at Stamford- based pharmaceutical company Purdue Pharma.
12/31/15 - Gilrose Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Dec. 31 Gilrose Pharmaceuticals, White Plains, New York, has been assigned a patent developed by two co-inventors for "pharmaceutical intervention and method for treating an apraxia of speech in children." The co-inventors are Bruce Roseman, White Plains, New York, and Gilla Kaplan, New York. Written by Amal Ahmed; edited by Jaya
12/31/15 - Global Blood Therapeutics Receives FDA Orphan Drug Designation for GBT440 in Sickle Cell Disease
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease.
12/31/15 - Insys Therapeutics, Inc. to Present at J.P. Morgan 34th Annual Healthcare Conference [Khaleej Times (United Arab Emirates)]
-Insys Therapeutics, Inc. today announced that Dan Brennan, Chief Operating Officer, and Darryl Baker, Chief Financial Officer, will present at the J.P. Morgan 34th Annual Healthcare Conference as follows:. About Insys Therapeutics, Inc.Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and no
12/31/15 - LifeSci Capital Initiates Coverage of TetraLogic Pharmaceuticals Corporation
NEW YORK, NY/ ACCESSWIRE/ December 31, 2015/ LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases.
12/31/15 - Manatee County fire department receives tool to help with heroin overdoses [The Bradenton Herald]
Dec. 30 MANATEE A Manatee County fire department has received a donation of a drug that will help in the fight against opioid overdose deaths. In July 2014, EVZIO became available in the U.S. by prescription and "is the first and only FDA- approved naloxone product specifically indicated for the emergency treatment of known or suspected opioid
12/31/15 - Market Overview on Proliferative Vitreoretinopathy (PVR) Global Clinical Trials Review, H2, 2015, Industry Analysis, Market Forecast to Dominate Pharma Industry
The Report Proliferative Vitreoretinopathy Global Clinical Trials Review, H2, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Proliferative Vitreoretinopathy Global Clinical...
12/31/15 - NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinsons Disease [Daily Tribune (Bahrain)]
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the companys continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments..
12/31/15 - PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs [Arab News (Saudi Arabia)]
-PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCytes pancreatic cancer and diabetes programs. Manuel Hidalgo, and experts at Translational Drug...
12/31/15 - Purdue Pharma Assigned Patent
ALEXANDRIA, Va., Dec. 31 Purdue Pharma, Stamford, Connecticut, has been assigned a patent developed by two co-inventors for buprenorphine analogs. The co-inventors are Donald J. Kyle, Yardley, Pennsylvania, and Laykea Tafesse, Robbinsville, New Jersey. Written by Kusum Sangma; edited by Jaya Anand.
12/31/15 - Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval...
Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Karla, Pradeep K.; Mangat, Harpal S., filed
12/31/15 - Researchers Submit Patent Application, "Overcap Intended for a Pharmaceutical Container", for Approval (USPTO 20150352012)
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventors PITTET, Michel; VALLOTTON, Raphael; LAMPRECHT, Volker, filed on January 22, 2014, was made available online on December 17, 2015. No assignee for this patent application has been made.
12/31/15 - Roche Submits Anti-Mullerian Hormone Assay for FDA Approval
By a News Reporter-Staff News Editor at Women's Health Weekly Roche announced that it has filed a direct de novo application to the U.S. Food and Drug Administration for a fully automated Anti-Mullerian assay for use on Roche's full portfolio of laboratory analyzers. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation. The assay is
12/31/15 - Strong Pipeline to Drive Global Women's Health Therapeutics Market, Says Transparency Market Research
Transparency Market Research Report Added "Women Health Therapeutics Market" to its database.Albany, NY 12/31/2015 The presence of several leading pharmaceutical companies in the development of women's health therapeutics is a key factor driving the global market, states Transparency Market Research in its latest report. The major drugs in th
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement